Technical Data
CDKN2A, phosphorylated (S8) (CDKN2A, CDKN2, MTS1, Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, Cyclin-dependent kinase 4 inhibitor A, Multiple tumor suppressor 1, p16-INK4a)
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Suitable for use in Dot Blot, ELISA

Recommended Dilution:
ELISA: 1:1,000
Dot blot 1:500

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
200ul-20CBlue IceHumanRabbit
As reported
CDKN2A Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S8 of human CDKN2A.
Purified by Protein A affinity chromatography.
Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Kovacs, E., et al. Proc. Natl. Acad. Sci. U.S.A. 107(12):5429-5434(2010) Irvine, M., et al. Cell Cycle 9(4):829-839(2010) Zhang, H.J., et al. J. Cell. Biochem. 106(3):464-472(2009) Ivanchuk, S.M., et al. Cell Cycle 7(12):1836-1850(2008) Bandyopadhyay, K., et al. Biochemistry 46(49):14325-14334(2007)